Graves Ophthalmopathy Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, Involved by DelveInsight | Novartis, AdvanceCor, Apitope, Worg Pharma, AV7 Ltd.

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Graves Ophthalmopathy pipeline constitutes 10+ key companies continuously working towards developing 10+ Graves Ophthalmopathy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Graves Ophthalmopathy Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Graves Ophthalmopathy Market.

 

The Graves Ophthalmopathy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Graves Ophthalmopathy Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Graves Ophthalmopathy treatment therapies with a considerable amount of success over the years. 

  • Graves Ophthalmopathy companies working in the treatment market are Immunovant Sciences GmbH, Horizon Pharma USA, Inc., Viridian Therapeutics, Inc., Tourmaline Bio, Inc., ACELYRIN Inc., Hoffmann-La Roche, Horizon Therapeutics USA, Inc., Lassen Therapeutics Inc., Novartis, Sling Therapeutics, Inc., Lassen Therapeutics, and others, are developing therapies for the Graves Ophthalmopathy treatment 

  • Emerging Graves Ophthalmopathy therapies in the different phases of clinical trials are- Batoclimab (IMVT 1401), RVT-1401, Teprotumumab, VRDN-001 10 mg/kg Drug, TOUR006 – 20 MG, IBI311, lonigutamab, Satralizumab, TEPEZZA, LASN01, CFZ533, linsitinib, LASN01, and others are expected to have a significant impact on the Graves Ophthalmopathy market in the coming years.   

  • In June 2024, US-based biotechnology firm Viridian Therapeutics has revealed plans to initiate two Phase III clinical trials for the anti-IGF-1R antibody, VRDN-003, targeting moderate-to-severe thyroid eye disease (TED). The trials, named REVEAL-1 and REVEAL-2, will evaluate the efficacy and safety of subcutaneous doses of VRDN-003 in patients with active and chronic TED, respectively.

  • In April 2024, Amgen (NASDAQ:AMGN) announced plans to submit a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for teprotumumab, a fully human monoclonal antibody and targeted inhibitor of the insulin-like growth factor-1 receptor (IGF-1R), intended for the treatment of moderate to severe Thyroid Eye Disease (TED) in adults. TED is a serious, progressive, debilitating, and potentially vision-threatening autoimmune disease that can cause proptosis (eye bulging), diplopia (double vision), eye pain, redness, and swelling. If approved, teprotumumab would be the first and only medication approved for TED in the European Union.

  • In August 2023, The US Food and Drug Administration (FDA) has approved Tourmaline Bio’s investigational new drug (IND) application, allowing the commencement of a Phase IIb trial for TOUR006 aimed at treating thyroid eye disease (TED), also known as Graves’ ophthalmopathy. This upcoming study will evaluate the effectiveness of 20mg and 50mg doses of TOUR006 compared to a placebo in patients with moderate to severe TED who are currently in the active phase of the disease.

 

Graves Ophthalmopathy Overview

Graves’ Ophthalmopathy, also known as Thyroid Eye Disease (TED) or Graves’ Orbitopathy, is an autoimmune inflammatory disorder associated with thyroid disease, particularly Graves’ disease. It affects the muscles and other tissues around the eyes, leading to various symptoms and complications.

 

Get a Free Sample PDF Report to know more about Graves Ophthalmopathy Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/graves-ophthalmopathy-pipeline-insight

 

Emerging Graves Ophthalmopathy Drugs Under Different Phases of Clinical Development Include:

  • Batoclimab (IMVT 1401): Immunovant Sciences

  • RVT-1401: Immunovant Sciences GmbH

  • Teprotumumab: Horizon Pharma USA, Inc.

  • VRDN-001 10 mg/kg Drug: Viridian Therapeutics, Inc.

  • Batoclimab: Immunovant Sciences GmbH

  • TOUR006 – 20 MG: Tourmaline Bio, Inc.

  • IBI311: Innovent Biologics (Suzhou) Co. Ltd.

  • lonigutamab: ACELYRIN Inc.

  • Satralizumab: Hoffmann-La Roche

  • TEPEZZA: Horizon Therapeutics USA, Inc.

  • LASN01: Lassen Therapeutics Inc.

  • CFZ533: Novartis

  • linsitinib: Sling Therapeutics, Inc.

  • LASN01: Lassen Therapeutics

 

Graves Ophthalmopathy Route of Administration

Graves Ophthalmopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral

  • Intravenous

  • Subcutaneous

  • Parenteral

  • Topical

 

Graves Ophthalmopathy Molecule Type

Graves Ophthalmopathy Products have been categorized under various Molecule types, such as

  • Recombinant fusion proteins

  • Small molecule

  • Monoclonal antibody

  • Peptide

  • Polymer

  • Gene therapy

 

Graves Ophthalmopathy Pipeline Therapeutics Assessment

  • Graves Ophthalmopathy Assessment by Product Type

  • Graves Ophthalmopathy By Stage and Product Type

  • Graves Ophthalmopathy Assessment by Route of Administration

  • Graves Ophthalmopathy By Stage and Route of Administration

  • Graves Ophthalmopathy Assessment by Molecule Type

  • Graves Ophthalmopathy by Stage and Molecule Type

 

DelveInsight’s Graves Ophthalmopathy Report covers around 10+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

 

Further Graves Ophthalmopathy product details are provided in the report. Download the Graves Ophthalmopathy pipeline report to learn more about the emerging Graves Ophthalmopathy therapies

 

Some of the key companies in the Graves Ophthalmopathy Therapeutics Market include:

Key companies developing therapies for Graves Ophthalmopathy are – Novartis, AdvanceCor, Apitope, Worg Pharmaceuticals, AV7 Limited, and others.

 

Graves Ophthalmopathy Pipeline Analysis:

The Graves Ophthalmopathy pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Graves Ophthalmopathy with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Graves Ophthalmopathy Treatment.

  • Graves Ophthalmopathy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Graves Ophthalmopathy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Graves Ophthalmopathy market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Graves Ophthalmopathy drugs and therapies

 

Graves Ophthalmopathy Pipeline Market Strengths

  • The recent US FDA approval of Horizon’s TEPEZZA has accelerated the research and development of GO.

  • Recent efforts to increase patient and clinician awareness of GO, with various awareness campaigns, are expected to increase early diagnosis and treatment of GO.

 

Graves Ophthalmopathy Pipeline Market Opportunities

  • Designing an effective molecule with an intended delivery mode that is matched to the intended target compartment is a necessary first step in ocular drug discovery programs.

  • Lack of availability of disease-modifying treatment for chronic patients, who have a significant impact on their emotional and social well-being.

 

Scope of Graves Ophthalmopathy Pipeline Drug Insight    

  • Coverage: Global

  • Key Graves Ophthalmopathy Companies: Immunovant Sciences GmbH, Horizon Pharma USA, Inc., Viridian Therapeutics, Inc., Tourmaline Bio, Inc., ACELYRIN Inc., Hoffmann-La Roche, Horizon Therapeutics USA, Inc., Lassen Therapeutics Inc., Novartis, Sling Therapeutics, Inc., Lassen Therapeutics, and others

  • Key Graves Ophthalmopathy Therapies: Batoclimab (IMVT 1401), RVT-1401, Teprotumumab, VRDN-001 10 mg/kg Drug, TOUR006 – 20 MG, IBI311, lonigutamab, Satralizumab, TEPEZZA, LASN01, CFZ533, linsitinib, LASN01, and others

  • Graves Ophthalmopathy Therapeutic Assessment: Graves Ophthalmopathy current marketed and Graves Ophthalmopathy emerging therapies

  • Graves Ophthalmopathy Market Dynamics: Graves Ophthalmopathy market drivers and Graves Ophthalmopathy market barriers 

 

Request for Sample PDF Report for Graves Ophthalmopathy Pipeline Assessment and clinical trials

 

Table of Contents

1. Graves Ophthalmopathy Report Introduction

2. Graves Ophthalmopathy Executive Summary

3. Graves Ophthalmopathy Overview

4. Graves Ophthalmopathy- Analytical Perspective In-depth Commercial Assessment

5. Graves Ophthalmopathy Pipeline Therapeutics

6. Graves Ophthalmopathy Late Stage Products (Phase II/III)

7. Graves Ophthalmopathy Mid Stage Products (Phase II)

8. Graves Ophthalmopathy Early Stage Products (Phase I)

9. Graves Ophthalmopathy Preclinical Stage Products

10. Graves Ophthalmopathy Therapeutics Assessment

11. Graves Ophthalmopathy Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Graves Ophthalmopathy Key Companies

14. Graves Ophthalmopathy Key Products

15. Graves Ophthalmopathy Unmet Needs

16 . Graves Ophthalmopathy Market Drivers and Barriers

17. Graves Ophthalmopathy Future Perspectives and Conclusion

18. Graves Ophthalmopathy Analyst Views

19. Appendix

20. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Graves Ophthalmopathy Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, Involved by DelveInsight | Novartis, AdvanceCor, Apitope, Worg Pharma, AV7 Ltd.